MarketCap
Facebook
X
TelegramCronos Group Operating Expenses 2011-2026 | CRON
Annual Operating Expenses Cronos Group
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 154 M | 98.2 M | 21.6 M | 7.43 M | 3.07 M | 1.55 M | 2.22 M | 424 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | 424 K | 36 M |
Operating Expenses of other stocks in the Drug manufacturers industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
196 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 3.23 | 4.53 % | $ 45.4 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Bausch Health Companies
BHC
|
4.96 B | $ 5.9 | 1.37 % | $ 2.15 B | Canada |
 |
Harrow Health
HROW
|
174 M | $ 41.5 | 2.09 % | $ 1.53 B | USA |
 |
Canopy Growth Corporation
CGC
|
197 M | $ 1.14 | -0.87 % | $ 123 M | Canada |
 |
Jupiter Wellness
JUPW
|
12.5 M | - | - | $ 33.6 M | USA |
 |
Pacira BioSciences
PCRX
|
279 M | $ 24.72 | 3.6 % | $ 1.14 B | USA |
 |
OrganiGram Holdings
OGI
|
41.4 M | $ 1.46 | -3.95 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
107 M | $ 4.69 | 3.53 % | $ 302 M | USA |
 |
Sundial Growers
SNDL
|
102 K | $ 1.51 | - | $ 3.37 M | Canada |
 |
Tilray
TLRY
|
1.52 B | $ 6.86 | 1.03 % | $ 4.24 B | Canada |
 |
Emergent BioSolutions
EBS
|
558 M | $ 8.81 | 2.2 % | $ 451 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
103 M | - | - | $ 193 M | Canada |
 |
Veru
VERU
|
44 M | $ 2.44 | -1.21 % | $ 329 M | USA |
 |
Organogenesis Holdings
ORGO
|
368 M | $ 2.5 | -1.96 % | $ 329 M | USA |
 |
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | USA |
 |
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | USA |
 |
cbdMD
YCBD
|
28.9 M | $ 0.79 | 5.76 % | $ 3.41 M | USA |
 |
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
133 M | $ 18.01 | -0.06 % | $ 115 M | USA |
 |
Relmada Therapeutics
RLMD
|
59.1 M | $ 7.48 | 6.86 % | $ 295 M | USA |
 |
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
36.7 M | $ 1.11 | 5.71 % | $ 55.4 M | USA |
 |
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
179 M | $ 8.63 | 2.86 % | $ 755 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 2.3 | 4.07 % | $ 2.85 M | USA |
 |
Viatris
VTRS
|
5.67 B | $ 14.68 | 4.78 % | $ 17.6 B | USA |
 |
Aurora Cannabis
ACB
|
183 M | $ 3.66 | 1.39 % | $ 86.3 M | Canada |
 |
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
31.1 M | $ 0.91 | -0.27 % | $ 32.7 M | USA |
 |
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
3.11 M | $ 0.67 | 1.67 % | $ 2.88 M |  China |
 |
TherapeuticsMD
TXMD
|
7.41 M | $ 2.07 | -0.48 % | $ 23.9 M | USA |